Thomas, 38, is a chemical engineer who initially presented in 2019 with optic neuritis followed two months later by a myelopathic episode. MRI was highly active with two gadolinium-enhancing T1 and multiple T2 lesions. EDSS was 2.5 (optic 1, sensory 2, bladder 2). Thomas had no relevant medical conditions other than obesity; his body weight was 120 kg (BMI 34 kg/m2) at presentation. Read More
CLINICAL CASES IN MS
Ken, a 53-year-old man, was initially seen in 2017 following onset of painful spasms in R leg and probable clonus while driving his car. He developed R leg weakness and band-like discomfort across his chest. He was worked up for stroke and cardiac issues and all investigations were negative. He had a prior history of asthma with nasal polyps and NSAID-associated dyspnea.
Michelle, 46, is a bank manager who was diagnosed with MS in 1996. She was initially treated with interferon-beta-1a 44 ug. She experienced ongoing clinical and radiological activity and was switched to natalizumab in 2013. She remained stable for seven years. In February 2020, Michelle noted that she used to be able to walk 2 km but could now only manage about 1 km. Her EDSS score showed no change over the past year. EDSS score was 3.0 (motor 2, cerebellar 2, sensory 2). She was started on 4-aminopyridine but obtained no benefit. Read More
Amanda, 31, a computer programmer was diagnosed with RRMS in 2014. She was initially treated with glatiramer acetate, but experienced ongoing disease activity. She was switched to fingolimod in 2016 and was clinically and radiologically stable for three years. Read More
Janet, 58, currently works full-time running an animal grooming business. She is married with two adult children. She was diagnosed in 1997 with RRMS after presenting with two mild relapses. MRI at that time revealed a low T2 burden of disease. She was initially hesitant about starting treatment. In 2003, she initiated therapy with interferon-beta-1b after experiencing a moderately-severe relapse with some residual disability. EDSS was 1.5. Read More